Modulation of carrier-induced epitopic suppression by Bordetella pertussis components and muramyl peptide.
Synthetic antigens employed in experimental synthetic vaccines are generally small haptenic peptides. Therefore, effective immunization with these antigens usually requires the use of an immunogenic carrier. Tetanus toxoid has been proposed for use as a carrier in future synthetic vaccines due to its high immunogenicity and acceptance for human use. Previous studies employing standard hapten/carrier systems such as DNP/KLH have demonstrated, however, that an epitope-specific suppression occurs when mice previously primed with carrier are subsequently immunized with an haptenic epitope conjugated to the same carrier. These same studies have shown that Bordetella pertussis vaccine administered at the time of carrier priming abrogates epitopic suppression. In the present investigation, epitopic suppression was studied in a synthetic vaccine model employing tetanus toxoid as a carrier. Results from these studies indicated that mice primed with tetanus toxoid 1 month before immunization with a peptide-tetanus toxoid conjugate exhibited enhanced secondary anti-tetanus toxin responses but decreased anti-peptide responses. Furthermore, injection of pertussis vaccine or purified B. pertussis toxin or endotoxin at the time of carrier priming could block the establishment of epitopic suppression. Administration of B. pertussis components enhanced antibody responses to both the carrier and the synthetic peptides as compared with responses of control animals. In addition, administration of an adjuvant-active nonpyrogenic derivative of muramyl dipeptide. Murabutide, with carrier priming reduced epitopic suppression of anti-peptide responses. B. pertussis toxin or endotoxin administered to mice previously suppressed by carrier priming with the first injection of carrier-peptide conjugate overcame epitopic suppression with resultant titers of anti-peptide antibody equal to or greater than nonsuppressed controls. These results suggest that the use of adjuvants with future synthetic vaccines may contribute the additional advantage of overcoming epitopic suppression, thus permitting the use of common, well-tolerated carrier systems such as tetanus toxoid in synthetic vaccine preparations.
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives* / Q000276:immunology; D000818:Animals; D001886:Bordetella pertussis / Q000276:immunology*; D002352:Carrier Proteins / Q000276:immunology; D004731:Endotoxins / Q000276:immunology; D000939:Epitopes; D005260:Female; D007074:Immunoglobulin G / Q000096:biosynthesis; D007165:Immunosuppression Therapy; D051379:Mice; D009842:Oligopeptides / Q000276:immunology*; D037342:Pertussis Toxin; D010567:Pertussis Vaccine / Q000276:immunology; D013745:Tetanus Toxoid / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology; D010566:Virulence Factors, Bordetella / Q000276:immunology
D002352:Carrier Proteins; D004731:Endotoxins; D000939:Epitopes; D007074:Immunoglobulin G; D009842:Oligopeptides; D010567:Pertussis Vaccine; D013745:Tetanus Toxoid; D014614:Vaccines, Synthetic; D010566:Virulence Factors, Bordetella; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C033575:murabutide; D037342:Pertussis Toxin